Use this for any post that you want on the home page
Phelan-McDermid syndrome is a rare genetic condition usually caused by a deletion or structural change at the end of chromosome 22, in a region called 22q13. Symptoms and severity can vary widely among people with Phelan-McDermid syndrome. For individuals with a chromosome 22 deletion, the size of the deletion may help explain some of these clinical differences. In general, larger 22q13 deletions are associated with more significant developmental delays and medical concerns. A recent study in 63 people with Phelan-McDermid syndrome further explored these genotype-phenotype relationships, helping researchers better understand how chromosome 22 deletion size may influence symptoms such as language development, motor function and development, and social behaviors as well as medical issues. This study also identified several candidate genes that could also be contributing to the symptoms seen in Phelan-McDermid syndrome.
Researchers at Ulm University in Germany have identified two promising blood-based biomarkers for Phelan-McDermid syndrome, including SHANK3 protein and beta-synuclein. In a pilot study of 23 individuals with Phelan-McDermid syndrome, lower SHANK3 levels and higher beta-synuclein levels were found compared to typically-developing controls. Individuals with Phelan-McDermid syndrome who had a history of regression had lower SHANK3 levels, and those with more significant language impairments had higher beta-synuclein levels. These findings also were observed in a Shank3 mouse model. Together, this suggests SHANK3 and beta-synuclein may be potential blood-based biomarkers in Phelan-McDermid syndrome. Although larger studies are needed to confirm the results, this research marks an important step toward identifying objective biological-based measures that may relate to disease severity and help monitor progression and evaluate treatment effectiveness.
The Castillo family’s 9th Annual #TeamMatthewLuis fundraiser raised more than $21,000 for Phelan-McDermid syndrome research and family support programs.
By: Meagan Hutchinson (PMSF Scientific Program Coordinator) and Lauren Schmitt, PhD (PMSF Chief Science Officer) Date: May 20, 2026 What Did…
By Lauren Schmitt, PhD3/26/2026Cincinnati Children’s Hospital Medical Center (Cincinnati, Ohio) is now home to the first multidisciplinary clinic specializing in Phelan-McDermid…
By Lauren Schmitt, PhDDate February 25, 2026Everyday, our families are taking their loved ones to clinic appointments, research visits, or under…
By: Meagan Hutchinson, Science & Research Administrator, PMSFFebruary 5, 2026Every year on the last day of February, the global rare disease…
In a recent preclinical study, researchers at McGill University found that metformin (an FDA-approved treatment for type 2 diabetes) improved behavior…
By Lauren Schmitt, PhDJanuary 12, 2026With Neuren's Phase 3 clinical trial for NNZ-2591 now open for enrollment, the recent publication of…
Registration is officially open for the 2026 PMSF Family Conference, The Climb We Make Together, Presented by Neuren Pharmaceuticals, and we’re…
